Abstract
Most hearing loss results from lesions of the sensory cells and/or neurons of the auditory portion of the inner ear. To date, only the cochlear implantation offers long-term hearing-aid benefit, but still with limited performance and expensive cost. While the underlying causes of deafness are not clear, the death or hair cells and/or neurons and the loss of neuronal contacts are key pathological features. Pinpointing molecular events that control cell death in the cochlea is critical for the development of new strategies to prevent and treat deafness, whether in combination or not with cochlear implant therapy.
Keywords: cochlea, cell death, ototoxicity, noise trauma, neuroprotection, trophic factors
Current Pharmaceutical Design
Title: Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Volume: 11 Issue: 17
Author(s): F. Lallemend, P. P. Lefebvre, G. Hans, G. Moonen and B. Malgrange
Affiliation:
Keywords: cochlea, cell death, ototoxicity, noise trauma, neuroprotection, trophic factors
Abstract: Most hearing loss results from lesions of the sensory cells and/or neurons of the auditory portion of the inner ear. To date, only the cochlear implantation offers long-term hearing-aid benefit, but still with limited performance and expensive cost. While the underlying causes of deafness are not clear, the death or hair cells and/or neurons and the loss of neuronal contacts are key pathological features. Pinpointing molecular events that control cell death in the cochlea is critical for the development of new strategies to prevent and treat deafness, whether in combination or not with cochlear implant therapy.
Export Options
About this article
Cite this article as:
Lallemend F., Lefebvre P. P., Hans G., Moonen G. and Malgrange B., Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies, Current Pharmaceutical Design 2005; 11 (17) . https://dx.doi.org/10.2174/1381612054367346
DOI https://dx.doi.org/10.2174/1381612054367346 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of the Primer Approximation Multiplex PCR (PAMP) Technique for Detecting Large Scale Cancer Genomic Lesions
Current Bioinformatics Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Current Drug Metabolism Metabolic Fate of Endocannabinoids
Current Neuropharmacology Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Taxotere Chemosensitivity Evaluation in Rat Breast Tumor by Multimodal Imaging: Quantitative Measurement by Fusion of MRI, PET Imaging with MALDI and Histology
Recent Patents on Medical Imaging Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases
Mini-Reviews in Medicinal Chemistry Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Expression and Function of Bcl-2 Proteins in Melanoma
Current Genomics Radiotherapy for Brain Tumors: Current Practice and Future Directions
Current Cancer Therapy Reviews Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets